[{"address1": "3020 Carrington Mill Blvd.", "address2": "Suite 475", "city": "Morrisville", "state": "NC", "zip": "27560", "country": "United States", "phone": "212 554 4484", "fax": "212 554 4531", "website": "https://www.tgtherapeutics.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. The company was incorporated in 1993 and is based in Morrisville, North Carolina.", "fullTimeEmployees": 338, "companyOfficers": [{"maxAge": 1, "name": "Mr. Michael S. Weiss Esq.", "age": 58, "title": "Chairman, CEO & President", "yearBorn": 1966, "fiscalYear": 2023, "totalPay": 1968759, "exercisedValue": 0, "unexercisedValue": 5090000}, {"maxAge": 1, "name": "Mr. Sean A. Power CPA", "age": 42, "title": "CFO, Corporate Secretary & Treasurer", "yearBorn": 1982, "fiscalYear": 2023, "totalPay": 670578, "exercisedValue": 0, "unexercisedValue": 3031375}, {"maxAge": 1, "name": "Ms. Jenna  Bosco", "title": "Senior Vice President of Corporate Communications", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Adam  Waldman", "title": "Chief Commercialization Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 9, "boardRisk": 10, "compensationRisk": 10, "shareHolderRightsRisk": 3, "overallRisk": 10, "governanceEpochDate": 1743465600, "compensationAsOfEpochDate": 1703980800, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 40.3, "open": 40.04, "dayLow": 39.51, "dayHigh": 41.37, "regularMarketPreviousClose": 40.3, "regularMarketOpen": 40.04, "regularMarketDayLow": 39.51, "regularMarketDayHigh": 41.37, "payoutRatio": 0.0, "beta": 2.136, "trailingPE": 275.53333, "forwardPE": 42.60825, "volume": 1463330, "regularMarketVolume": 1463330, "averageVolume": 2688939, "averageVolume10days": 2265300, "averageDailyVolume10Day": 2265300, "bid": 35.26, "ask": 46.71, "bidSize": 1, "askSize": 1, "marketCap": 6491745280, "fiftyTwoWeekLow": 12.93, "fiftyTwoWeekHigh": 43.32, "priceToSalesTrailing12Months": 19.731508, "fiftyDayAverage": 36.8384, "twoHundredDayAverage": 29.126125, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 5945611264, "profitMargins": 0.07107, "floatShares": 134539735, "sharesOutstanding": 157071008, "sharesShort": 23543502, "sharesShortPriorMonth": 26233481, "sharesShortPreviousMonthDate": 1741910400, "dateShortInterest": 1744675200, "sharesPercentSharesOut": 0.1499, "heldPercentInsiders": 0.093789995, "heldPercentInstitutions": 0.6272, "shortRatio": 8.19, "shortPercentOfFloat": 0.16540001, "impliedSharesOutstanding": 157071008, "bookValue": 1.544, "priceToBook": 26.768135, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1735603200, "netIncomeToCommon": 23383000, "trailingEps": 0.15, "forwardEps": 0.97, "lastSplitFactor": "100:5625", "lastSplitDate": 1335744000, "enterpriseToRevenue": 18.072, "enterpriseToEbitda": 141.572, "52WeekChange": 2.1028528, "SandP52WeekChange": 0.07995045, "quoteType": "EQUITY", "currentPrice": 41.33, "targetHighPrice": 55.0, "targetLowPrice": 11.0, "targetMeanPrice": 43.0, "targetMedianPrice": 48.0, "recommendationMean": 1.625, "recommendationKey": "buy", "numberOfAnalystOpinions": 6, "totalCash": 311000000, "totalCashPerShare": 2.141, "ebitda": 41997000, "totalDebt": 254380000, "quickRatio": 4.854, "currentRatio": 6.246, "totalRevenue": 329004000, "debtToEquity": 114.398, "revenuePerShare": 2.264, "returnOnAssets": 0.05777, "returnOnEquity": 0.122150004, "grossProfits": 290518016, "freeCashflow": -62020876, "operatingCashflow": -40517000, "revenueGrowth": 1.46, "grossMargins": 0.88302004, "ebitdaMargins": 0.12765001, "operatingMargins": 0.27683002, "financialCurrency": "USD", "symbol": "TGTX", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "corporateActions": [], "shortName": "TG Therapeutics, Inc.", "longName": "TG Therapeutics, Inc.", "marketState": "CLOSED", "earningsTimestamp": 1741003200, "earningsTimestampStart": 1745929800, "earningsTimestampEnd": 1746448200, "earningsCallTimestampStart": 1741008600, "earningsCallTimestampEnd": 1741008600, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": 0.15, "epsForward": 0.97, "epsCurrentYear": 1.024, "priceEpsCurrentYear": 40.36133, "fiftyDayAverageChange": 4.4916, "fiftyDayAverageChangePercent": 0.12192711, "twoHundredDayAverageChange": 12.2038765, "twoHundredDayAverageChangePercent": 0.41900104, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "1.6 - Buy", "cryptoTradeable": false, "regularMarketChangePercent": 2.5558376, "regularMarketPrice": 41.33, "exchange": "NCM", "messageBoardId": "finmb_143627354", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "postMarketTime": 1745625530, "regularMarketTime": 1745611202, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1272893400000, "postMarketChangePercent": 0.401157, "postMarketPrice": 41.4958, "postMarketChange": 0.165798, "regularMarketChange": 1.0300026, "regularMarketDayRange": "39.51 - 41.37", "fullExchangeName": "NasdaqCM", "averageDailyVolume3Month": 2688939, "fiftyTwoWeekLowChange": 28.400002, "fiftyTwoWeekLowChangePercent": 2.1964424, "fiftyTwoWeekRange": "12.93 - 43.32", "fiftyTwoWeekHighChange": -1.9899979, "fiftyTwoWeekHighChangePercent": -0.045937162, "fiftyTwoWeekChangePercent": 210.28528, "displayName": "TG Therapeutics", "trailingPegRatio": null, "__fetch_time": "2025-04-26"}]